A month has gone by since the last earnings report for C.R. Bard, Inc. . Shares have added about 8.2% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock’s next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
C.R. Bard Beats Past Q4 Earnings & Sales Estimates
Murray Hill, NJ-based C.R. Bard Inc. reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by $0.04 and also improving from the year-ago quarterly number of $2.43.
Net sales during the fourth quarter of 2016 increased from $870.8 million on a year-over-year basis to $967.1 million, better than the Zacks Consensus Estimate of $956 million.
Quarter Highlights
Net sales in the U.S. were $655.0 million and net sales outside the U.S. were $312.1 million, an increase of 8% and 18%, respectively, over the prior-year period.
Segment Details
Vascular product sales increased 9% year over year (up 10% at cc) to $262.0 million.
Coming to Urology, sales increased 16% on a year-over-year basis (up 18% at cc) to $253.0 million.
Oncology sales were up 9% (up 10% at cc) to $259.4 million.
Surgical Specialties sales were up 9% (up 10% at cc) to $167.2 million.
Sales from the ‘other product line’ increased 11% on a year-over-year basis to almost $25.5 million.
Guidance
For full-year 2017, C.R. Bard projects net sales to increase between 4% and 5% on an as-reported basis. Excluding the impact of foreign exchange, full year 2017 net sales are forecasted to increase between 6% and 6.5% over 2016. Full year 2017 earnings per share, after adjusting for amortization of intangibles are projected to be between $11.45 and $11.75, representing growth between 11% and 14% compared to full year 2016 results.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions
VGM Scores
At this time, C.R. Bard's stock has a subpar Growth Score of 'D', while its Momentum is doing a bit better with 'C'. Charting a somewhat similar path, the stock was allocated a grade of 'C' on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregte VGM Score of 'D'. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is suitable for value and momentum investors.
Outlook
The stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.
Image: Bigstock
C.R. Bard (BCR) Up 8.2% Since Earnings Report: Can It Continue?
A month has gone by since the last earnings report for C.R. Bard, Inc. . Shares have added about 8.2% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock’s next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
C.R. Bard Beats Past Q4 Earnings & Sales Estimates
Murray Hill, NJ-based C.R. Bard Inc. reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by $0.04 and also improving from the year-ago quarterly number of $2.43.
Net sales during the fourth quarter of 2016 increased from $870.8 million on a year-over-year basis to $967.1 million, better than the Zacks Consensus Estimate of $956 million.
Quarter Highlights
Net sales in the U.S. were $655.0 million and net sales outside the U.S. were $312.1 million, an increase of 8% and 18%, respectively, over the prior-year period.
Segment Details
Vascular product sales increased 9% year over year (up 10% at cc) to $262.0 million.
Coming to Urology, sales increased 16% on a year-over-year basis (up 18% at cc) to $253.0 million.
Oncology sales were up 9% (up 10% at cc) to $259.4 million.
Surgical Specialties sales were up 9% (up 10% at cc) to $167.2 million.
Sales from the ‘other product line’ increased 11% on a year-over-year basis to almost $25.5 million.
Guidance
For full-year 2017, C.R. Bard projects net sales to increase between 4% and 5% on an as-reported basis. Excluding the impact of foreign exchange, full year 2017 net sales are forecasted to increase between 6% and 6.5% over 2016. Full year 2017 earnings per share, after adjusting for amortization of intangibles are projected to be between $11.45 and $11.75, representing growth between 11% and 14% compared to full year 2016 results.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions
C.R. Bard, Inc. Price and Consensus
C.R. Bard, Inc. Price and Consensus | C.R. Bard, Inc. Quote
VGM Scores
At this time, C.R. Bard's stock has a subpar Growth Score of 'D', while its Momentum is doing a bit better with 'C'. Charting a somewhat similar path, the stock was allocated a grade of 'C' on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregte VGM Score of 'D'. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is suitable for value and momentum investors.
Outlook
The stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.